Dermatologic Use of Medical Cannabis Use Lags Behind Interest Dermatologic Use of Medical Cannabis Use Lags Behind Interest
The most common indication among the respondents with dermatologist recommendations for products requiring a medical card was for acne (68%), followed by psoriasis and rosacea (28% each).Medscape Medical News (Source: Medscape Dermatology Headlines)
Source: Medscape Dermatology Headlines - January 20, 2022 Category: Dermatology Tags: Dermatology News Source Type: news

Dermatologic Use of Medical Cannabis Lags Behind Interest Dermatologic Use of Medical Cannabis Lags Behind Interest
The most common indication among the respondents with dermatologist recommendations for products requiring a medical card was for acne (68%), followed by psoriasis and rosacea (28% each).Medscape Medical News (Source: Medscape Rheumatology Headlines)
Source: Medscape Rheumatology Headlines - January 20, 2022 Category: Rheumatology Tags: Dermatology News Source Type: news

Psoriasis Education Tool for Decision-Making About Biologics Psoriasis Education Tool for Decision-Making About Biologics
This study found that the use of a visual aid may help psoriasis patients better retain information during counseling and reduce anxiety and uncertainty when starting biologic treatment.Skin Therapy Letter (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - January 20, 2022 Category: Consumer Health News Tags: Dermatology Journal Article Source Type: news

Specialist-Led Model of Care Can Improve CVD Prevention in Psoriasis
WEDNESDAY, Jan. 19, 2022 -- Dermatologists and patients with psoriatic disease have a positive view of a specialist-led model of care to improve cardiovascular disease (CVD) prevention, according to a study published online Jan. 19 in JAMA... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - January 19, 2022 Category: Pharmaceuticals Source Type: news

Dermaliq Therapeutics Signs USD 15 Million Series A Round to Advance Three Transformative Drug Therapies into Clinical Trials
Dermaliq Therapeutics, Inc. is an independent private pharmaceutical company emerged from Novaliq Spin-off to unlock value in the space of medical dermatology by using Novaliq's transformative technology outside eye care 3E Bioventures Capital and Be... Biopharmaceuticals, Dermatology, Venture Capital Dermaliq Therapeutics, alopecia, psoriasis, soft tissue infection (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - January 18, 2022 Category: Pharmaceuticals Source Type: news

CBD and Cannabis Products for Acne, Psoriasis? Buyer Beware, Dermatologists Say
Title: CBD and Cannabis Products for Acne, Psoriasis? Buyer Beware, Dermatologists SayCategory: Health NewsCreated: 1/17/2022 12:00:00 AMLast Editorial Review: 1/18/2022 12:00:00 AM (Source: MedicineNet Skin General)
Source: MedicineNet Skin General - January 18, 2022 Category: Dermatology Source Type: news

Secukinumab vs. Adalimumab in Psoriatic Arthritis and Psoriasis Secukinumab vs. Adalimumab in Psoriatic Arthritis and Psoriasis
The results of this study provide evidence that the IL-17 inhibitor secukinumab is effective in managing the concomitant features of psoriasis and psoriatic arthritis.The British Journal of Dermatology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - January 4, 2022 Category: Consumer Health News Tags: Dermatology Journal Article Source Type: news

Can You Treat Eczema and Psoriasis the Same Way?
Title: Can You Treat Eczema and Psoriasis the Same Way?Category: Diseases and ConditionsCreated: 1/3/2022 12:00:00 AMLast Editorial Review: 1/3/2022 12:00:00 AM (Source: MedicineNet Skin General)
Source: MedicineNet Skin General - January 3, 2022 Category: Dermatology Source Type: news

FDA to Review Topical PDE4-Inhibitor Roflumilast for Psoriasis FDA to Review Topical PDE4-Inhibitor Roflumilast for Psoriasis
In an open label phase 2b study of roflumilast, the treatment effect lasted for 52-64 weeks, according to the manufacturer.Medscape Medical News (Source: Medscape Dermatology Headlines)
Source: Medscape Dermatology Headlines - December 30, 2021 Category: Dermatology Tags: Dermatology News Source Type: news

Spesolimab Speeds Lesion Clearance in Rare Type Of Psoriasis Spesolimab Speeds Lesion Clearance in Rare Type Of Psoriasis
The anti-interleukin 36 receptor monoclonal antibody is under priority review at the Food and Drug Administration for treating GPP flares.Medscape Medical News (Source: Medscape Rheumatology Headlines)
Source: Medscape Rheumatology Headlines - December 27, 2021 Category: Rheumatology Tags: Dermatology News Source Type: news

Spesolimab Clears Lesions in Generalized Pustular Psoriasis
MONDAY, Dec. 27, 2021 -- At one week, the incidence of lesion clearance was higher with spesolimab than placebo among patients with generalized pustular psoriasis (GPP), according to a study published in the Dec. 23 issue of the New England Journal... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - December 27, 2021 Category: Pharmaceuticals Source Type: news

FDA Accepts Arcutis Biotherapeutics ’ New Drug Application for Roflumilast Cream for Adults and Adolescents with Plaque Psoriasis
FDA has set a target action date of July 29, 2022 NDA supported by positive efficacy data from the pivotal Phase 3 DERMIS 1 and DERMIS 2 clinical studies, as well as results from the long-term safety study If approved, roflumilast cream would... (Source: Drugs.com - New Drug Applications)
Source: Drugs.com - New Drug Applications - December 22, 2021 Category: Drugs & Pharmacology Source Type: news

AI Allows Automated Scoring of Psoriasis Area, Severity
TUESDAY, Dec. 21, 2021 -- Deep learning algorithms, such as convolutional neural networks (CNNs), can automatically and objectively perform image-based Psoriasis Area and Severity Index (PASI) scoring, according to a study published in the January... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - December 21, 2021 Category: Pharmaceuticals Source Type: news

' Freedom From Disease' in Psoriasis Is Multicomponent Concept
MONDAY, Dec. 20, 2021 -- For people with psoriasis, " freedom from disease " is a multicomponent concept that includes five main domains, according to research published online Nov. 24 in the Journal of the European Academy of Dermatology and... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - December 20, 2021 Category: Pharmaceuticals Source Type: news

FDA Approves Otezla (apremilast) for the Treatment of Adult Patients with Plaque Psoriasis, Regardless of Severity Level
THOUSAND OAKS, Calif., Dec. 20, 2021 /PRNewswire/ -- Amgen (NASDAQ: AMGN) today announced that the U.S. Food and Drug Administration (FDA) has approved Otezla® (apremilast) for the treatment of adult patients with plaque psoriasis who are... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - December 20, 2021 Category: Drugs & Pharmacology Source Type: news